company background image
LVTX

LAVA Therapeutics NasdaqGS:LVTX Stock Report

Last Price

US$2.51

Market Cap

US$64.7m

7D

-5.4%

1Y

-56.3%

Updated

15 Aug, 2022

Data

Company Financials +
LVTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LVTX Stock Overview

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.

LAVA Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LAVA Therapeutics
Historical stock prices
Current Share PriceUS$2.51
52 Week HighUS$8.38
52 Week LowUS$2.28
Beta0
1 Month Change-5.64%
3 Month Change-29.89%
1 Year Change-56.27%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.45%

Recent News & Updates

Shareholder Returns

LVTXUS BiotechsUS Market
7D-5.4%1.4%3.6%
1Y-56.3%-19.6%-9.6%

Return vs Industry: LVTX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: LVTX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is LVTX's price volatile compared to industry and market?
LVTX volatility
LVTX Average Weekly Movement12.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: LVTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: LVTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201657Steve Hurlyhttps://www.lavatherapeutics.com

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

LAVA Therapeutics Fundamentals Summary

How do LAVA Therapeutics's earnings and revenue compare to its market cap?
LVTX fundamental statistics
Market CapUS$64.70m
Earnings (TTM)-US$36.16m
Revenue (TTM)US$5.00m

12.9x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LVTX income statement (TTM)
RevenueUS$5.00m
Cost of RevenueUS$26.08m
Gross Profit-US$21.08m
Other ExpensesUS$15.08m
Earnings-US$36.16m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.40
Gross Margin-421.64%
Net Profit Margin-723.20%
Debt/Equity Ratio4.2%

How did LVTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LVTX?

Other financial metrics that can be useful for relative valuation.

LVTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does LVTX's PS Ratio compare to its peers?

LVTX PS Ratio vs Peers
The above table shows the PS ratio for LVTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.8x
ATHX Athersys
6.4x-38.4%US$70.3m
HARP Harpoon Therapeutics
3.1x36.6%US$70.8m
SLS SELLAS Life Sciences Group
66.6x79.6%US$66.6m
ICCC ImmuCell
3.1xn/aUS$63.1m
LVTX LAVA Therapeutics
12.9x-34.4%US$64.7m

Price-To-Sales vs Peers: LVTX is good value based on its Price-To-Sales Ratio (12.9x) compared to the peer average (19.8x).


Price to Earnings Ratio vs Industry

How does LVTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: LVTX is good value based on its Price-To-Sales Ratio (12.9x) compared to the US Biotechs industry average (17.2x)


Price to Sales Ratio vs Fair Ratio

What is LVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LVTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.9x
Fair PS Ratio0.005x

Price-To-Sales vs Fair Ratio: LVTX is expensive based on its Price-To-Sales Ratio (12.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of LVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LVTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LVTX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is LAVA Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-7.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LVTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LVTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LVTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LVTX's revenue is expected to decline over the next 3 years (-34.4% per year).

High Growth Revenue: LVTX's revenue is forecast to decline over the next 3 years (-34.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LVTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has LAVA Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-16.9%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: LVTX is currently unprofitable.

Growing Profit Margin: LVTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LVTX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: LVTX has a negative Return on Equity (-33.36%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is LAVA Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LVTX's short term assets ($126.7M) exceed its short term liabilities ($16.3M).

Long Term Liabilities: LVTX's short term assets ($126.7M) exceed its long term liabilities ($4.8M).


Debt to Equity History and Analysis

Debt Level: LVTX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if LVTX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LVTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LVTX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 57.1% each year.


Discover healthy companies

Dividend

What is LAVA Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LVTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LVTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LVTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LVTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LVTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Steve Hurly (54 yo)

3.17yrs

Tenure

Mr. Stephen Allen Hurly, also known as Steve, MSc, MBA, serves as Chief Executive Officer, President and Executive Director at Lava Therapeutics N.V. since June 2019. Mr. Hurly was Chief Executive Officer...


Leadership Team

Experienced Management: LVTX's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: LVTX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

LAVA Therapeutics N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: LAVA Therapeutics N.V.
  • Ticker: LVTX
  • Exchange: NasdaqGS
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$64.699m
  • Shares outstanding: 25.78m
  • Website: https://www.lavatherapeutics.com

Number of Employees


Location

  • LAVA Therapeutics N.V.
  • Yalelaan 60
  • Utrecht
  • Utrecht
  • 3584 CM
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.